Literature DB >> 22201209

Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment.

H Nasrallah1, R Tandon, M Keshavan.   

Abstract

BACKGROUND: Although schizophrenia has been considered a distinct disease entity for the past century, its precise definition and etio-pathophysiology remain obscure and its treatment remains unsatisfactory. In this review, we summarize our state of knowledge about the etiology, pathophysiology, clinical features, and treatment of schizophrenia. METHODOLOGICAL ISSUES: The inadequacy of the major conceptual models of schizophrenia is a major roadblock in providing a coherent explanation for the known facts of this illness, despite these limitations and its changing definitions, the construct of schizophrenia does convey useful information: (i) patients diagnosed as having schizophrenia do have a real disease--they experience both suffering and disability; (ii) a diagnosis of schizophrenia does suggest a distinctive clinical profile--a characteristic long-term course; an admixture of positive, negative, and cognitive symptoms; (iii) a diagnosis of schizophrenia has clear treatment and prognostic implications--likelihood of benefit from antipsychotic treatment and likelihood of incomplete recovery; and (iv) schizophrenia satisfies criteria for a valid diagnostic entity better than almost any other psychiatric diagnosis. DISCUSSION: On the other hand, the concept of schizophrenia has serious shortcomings. First, it is not a single disease entity--it has multiple etiological factors and pathophysiological mechanisms but common phenotypic features. Second, its clinical manifestations are so diverse that its extreme variability has been considered by some to be a core feature. Third, its boundaries remain ill defined and not clearly demarcated from other clinical entities.
CONCLUSIONS: A necessary next step is to deconstruct schizophrenia as an entity into component dimensions--endophenotypes linked to unique etiological and pathophysiological processes that may yield unique treatment targets. Innovative approaches are needed to elucidate the biological substrates of these entities because such clarity is vital for replicable research. We conclude by identifying the critical gaps in our knowledge, and unmet needs in our approaches to care, and outline steps that can move the field forward.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22201209     DOI: 10.1017/s204579601100062x

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  12 in total

1.  'Young people at high risk for psychosis: conceptual framework, research evidence and treatment opportunities'.

Authors:  Antonio Lasalvia; Michele Tansella
Journal:  Epidemiol Psychiatr Sci       Date:  2012-09-11       Impact factor: 6.892

2.  Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia.

Authors:  Matthew W Rice; Rosalinda C Roberts; Miguel Melendez-Ferro; Emma Perez-Costas
Journal:  Brain Struct Funct       Date:  2014-10-01       Impact factor: 3.270

Review 3.  Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.

Authors:  Xiangyou Hu; Qingyuan Fan; Hailong Hou; Riqiang Yan
Journal:  J Neurochem       Date:  2015-11-13       Impact factor: 5.372

4.  Epidemiological and clinical characterization following a first psychotic episode in major depressive disorder: comparisons with schizophrenia and bipolar I disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).

Authors:  Olabisi Owoeye; Tara Kingston; Paul J Scully; Patrizia Baldwin; David Browne; Anthony Kinsella; Vincent Russell; Eadbhard O'Callaghan; John L Waddington
Journal:  Schizophr Bull       Date:  2013-05-28       Impact factor: 9.306

5.  Acute N-methyl-D-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats.

Authors:  I Feinstein; M F Kritzer
Journal:  Neuroscience       Date:  2012-10-22       Impact factor: 3.590

Review 6.  New drug developments in psychosis: Challenges, opportunities and strategies.

Authors:  Matcheri S Keshavan; Ashley N Lawler; Henry A Nasrallah; Rajiv Tandon
Journal:  Prog Neurobiol       Date:  2016-08-09       Impact factor: 11.685

7.  The use of a Cumulative Needs for Care Monitor for individual treatment v. care as usual for patients diagnosed with severe mental illness, a cost-effectiveness analysis from the health care perspective.

Authors:  M Drukker; M Joore; J van Os; S Sytema; G Driessen; M Bak; Ph Delespaul
Journal:  Epidemiol Psychiatr Sci       Date:  2012-05-22       Impact factor: 6.892

Review 8.  Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Authors:  Michael E Salacz; Richard E Kast; Najmaldin Saki; Ansgar Brüning; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

9.  Rethinking Schizophrenia in the Context of the Person and Their Circumstances: Seven Reasons.

Authors:  Marino Pérez-Álvarez; José M García-Montes; Oscar Vallina-Fernández; Salvador Perona-Garcelán
Journal:  Front Psychol       Date:  2016-11-03

10.  Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.

Authors:  Suresh Durgam; Robert E Litman; Kelly Papadakis; Dayong Li; György Németh; István Laszlovszky
Journal:  Int Clin Psychopharmacol       Date:  2016-03       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.